Wenwei Hu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9082444/publications.pdf

Version: 2024-02-01

60 papers	7,382 citations	87888 38 h-index	138484 58 g-index
62 all docs	62 docs citations	62 times ranked	10619 citing authors

#	Article	IF	Citations
1	A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans. Cell, 2004, 119, 591-602.	28.9	1,158
2	Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7455-7460.	7.1	697
3	p53 regulates maternal reproduction through LIF. Nature, 2007, 450, 721-724.	27.8	387
4	Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16259-16264.	7.1	342
5	Tumour-associated mutant p53 drives the Warburg effect. Nature Communications, 2013, 4, 2935.	12.8	329
6	Negative Regulation of Tumor Suppressor p53 by MicroRNA miR-504. Molecular Cell, 2010, 38, 689-699.	9.7	285
7	Declining p53 function in the aging process: A possible mechanism for the increased tumor incidence in older populations. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16633-16638.	7.1	243
8	The Origins and Evolution of the p53 Family of Genes. Cold Spring Harbor Perspectives in Biology, 2010, 2, a001198-a001198.	5.5	239
9	Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy. Journal of Molecular Biology, 2017, 429, 1595-1606.	4.2	219
10	Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Letters, 2015, 356, 197-203.	7.2	210
11	Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9761-9766.	7.1	175
12	Tumor suppressor p53 and metabolism. Journal of Molecular Cell Biology, 2019, 11, 284-292.	3.3	174
13	Chronic restraint stress attenuates p53 function and promotes tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7013-7018.	7.1	156
14	LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nature Communications, 2014, 5, 5218.	12.8	152
15	Parkin targets HIF-1Î± for ubiquitination and degradation to inhibit breast tumor progression. Nature Communications, 2017, 8, 1823.	12.8	151
16	Gain-of-function mutant p53 in cancer progression and therapy. Journal of Molecular Cell Biology, 2020, 12, 674-687.	3.3	146
17	The Regulation of Multiple p53 Stress Responses is Mediated through MDM2. Genes and Cancer, 2012, 3, 199-208.	1.9	128
18	LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget, 2014, 5, 788-801.	1.8	128

#	Article	IF	Citations
19	The regulation of MDM2 oncogene and its impact on human cancers. Acta Biochimica Et Biophysica Sinica, 2014, 46, 180-189.	2.0	125
20	The Regulation of Ferroptosis by Tumor Suppressor p53 and its Pathway. International Journal of Molecular Sciences, 2020, 21, 8387.	4.1	122
21	The tumor suppressor p53: Cancer and aging. Cell Cycle, 2008, 7, 842-847.	2.6	106
22	A Single Nucleotide Polymorphism in the MDM2 Gene Disrupts the Oscillation of p53 and MDM2 Levels in Cells. Cancer Research, 2007, 67, 2757-2765.	0.9	104
23	Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway. Genes and Cancer, 2010, 1, 360-368.	1.9	101
24	Cullin3â€“KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression. Genes and Development, 2016, 30, 1956-1970.	5.9	100
25	Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis. Nature Communications, 2013, 4, 2996.	12.8	94
26	Winter Temperature and UV Are Tightly Linked to Genetic Changes in the p53 Tumor Suppressor Pathway in Eastern Asia. American Journal of Human Genetics, 2009, 84, 534-541.	6.2	83
27	Tumor suppressor p53 negatively regulates glycolysis stimulated by hypoxia through its target RRAD. Oncotarget, 2014, 5, 5535-5546.	1.8	81
28	p53: A new player in reproduction. Cell Cycle, 2008, 7, 848-852.	2.6	80
29	Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis. ELife, 2016, 5, e10727.	6.0	79
30	Regulation of female reproduction by p53 and its family members. FASEB Journal, 2011, 25, 2245-2255.	0.5	71
31	The Role of p53 Gene Family in Reproduction. Cold Spring Harbor Perspectives in Biology, 2009, 1, a001073-a001073.	5.5	70
32	Lycorine Promotes Autophagy and Apoptosis via TCRP1/Akt/mTOR Axis Inactivation in Human Hepatocellular Carcinoma. Molecular Cancer Therapeutics, 2017, 16, 2711-2723.	4.1	67
33	Leukemia inhibitory factor promotes EMT through STAT3-dependent miR-21 induction. Oncotarget, 2016, 7, 3777-3790.	1.8	65
34	BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function. ELife, 2015, 4, .	6.0	61
35	Differential levels of transcription of p53â€regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. FASEB Journal, 2010, 24, 1347-1353.	0.5	60
36	The Regulation of Leukemia Inhibitory Factor. Cancer Cell & Microenvironment, 2015, 2, .	0.8	51

#	Article	IF	Citations
37	Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression. Journal of Clinical Investigation, 2020, 130, 3253-3269.	8.2	51
38	HIF-2Î± mediates hypoxia-induced LIF expression in human colorectal cancer cells. Oncotarget, 2015, 6, 4406-4417.	1.8	42
39	Regulation of Fertility by the p53 Family Members. Genes and Cancer, 2011, 2, 420-430.	1.9	37
40	microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis. Oncotarget, 2016, 7, 8783-8796.	1.8	36
41	A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models. ELife, 2018, 7, .	6.0	36
42	Parkinson's diseaseâ€associated protein Parkin: an unusual player in cancer. Cancer Communications, 2018, 38, 1-8.	9.2	36
43	Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression. Genes and Development, 2017, 31, 1641-1654.	5.9	35
44	The emerging role of leukemia inhibitory factor in cancer and therapy. , 2021, 221, 107754.		34
45	Tumor suppressor p53 cross-talks with TRIM family proteins. Genes and Diseases, 2021, 8, 463-474.	3.4	33
46	The Interplay Between Tumor Suppressor p53 and Hypoxia Signaling Pathways in Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 648808.	3.7	33
47	TP53 Gain-of-Function and Nonâ€“Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2022, 40, 171-179.	1.6	33
48	A novel mutant p53 binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in tumorigenesis. Cell Discovery, 2016, 2, 16039.	6.7	26
49	LIF is essential for ISC function and protects against radiation-induced gastrointestinal syndrome. Cell Death and Disease, 2020, 11, 588.	6.3	22
50	Tumor suppressor p53 regulates intestinal type 2 immunity. Nature Communications, 2021, 12, 3371.	12.8	19
51	Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis. Cell Cycle, 2020, 19, 1338-1351.	2.6	18
52	A genetic variant in p63 (rs17506395) is associated with breast cancer susceptibility and prognosis. Gene, 2014, 535, 170-176.	2.2	10
53	EC330, a small-molecule compound, is a potential novel inhibitor of LIF signaling. Journal of Molecular Cell Biology, 2020, 12, 477-480.	3.3	9
54	LIF is a new p53 negative regulator. Journal of Nature and Science, 2015, 1, e131.	1.1	9

#	Article	IF	Citations
55	Tumor suppressor p53: new functions of an old protein. Frontiers in Biology, 2011, 6, 58-68.	0.7	7
56	TRIM32 is a novel negative regulator of p53. Molecular and Cellular Oncology, 2015, 2, e970951.	0.7	7
57	Leukemia inhibitory factor drives glucose metabolic reprogramming to promote breast tumorigenesis. Cell Death and Disease, 2022, 13, 370.	6.3	5
58	Genetic and stochastic influences upon tumor formation and tumor types in Li-Fraumeni mouse models. Life Science Alliance, 2021, 4, e202000952.	2.8	4
59	Pontin, a novel interactor of mutant p53 that promotes mutant p53 gain of function. Molecular and Cellular Oncology, 2016, 3, e1076587.	0.7	1
60	microRNAs and tumor suppressor p53 regulation. , 2022, , 37-46.		0